Gilead Sciences GILD
NASDAQ GILD
$144.80 -0.85 (-0.58%)
As of: Sep 10, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Asset Utilization Ratio (2009 - 2026)

Gilead Sciences' (GILD) quarterly Asset Utilization Ratio came in at 0.58 in Q2 2026, up 12.03% on a YoY basis from 0.51 in Q2 2025, and up 11.79% quarter-over-quarter from 0.52 in Q1 2026.

Analysis

Gilead Sciences (GILD) Asset Utilization Ratio (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Asset Utilization Ratio for 18 consecutive years, with 0.58 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Asset Utilization Ratio rose 12.03% year-over-year to 0.58; the trailing twelve-month figure through Jun 2026 stood at 0.58 (up 12.03% YoY), and the FY2025 full-year result was 0.5, up 5.09% from the prior year.
  • Asset Utilization Ratio rose to 0.58 in Q2 2026 per GILD's latest filing, from 0.52 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.58 in Q2 2026 and bottomed at 0.42 in Q1 2022.
  • Historically, Asset Utilization Ratio has averaged 0.48 across 5 years, with a median of 0.48 in 2025.
  • The sharpest annual moves came in 2024 and 2025: Asset Utilization Ratio rose 19.19% in 2024, then dropped 2.75% in 2025.
  • Over 5 years, Asset Utilization Ratio stood at 0.43 in 2022, then gained by 0.38% to 0.44 in 2023, then gained by 16.3% to 0.51 in 2024, then declined by 1.12% to 0.5 in 2025, then advanced by 15.11% to 0.58 in 2026.
  • According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.58, 0.52, and 0.5 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 0.40
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 0.58
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 0.47
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 0.38
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 0.20
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 0.90
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 0.33
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 0.00
10 Insmed 27.67 Bn 26.51 Bn 358.27 Mn 0.54
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.58
Mar 31, 2026 0.52
Dec 31, 2025 0.50
Sep 30, 2025 0.51
Jun 30, 2025 0.51
Mar 31, 2025 0.50
Dec 31, 2024 0.51
Sep 30, 2024 0.52
Jun 30, 2024 0.51
Mar 31, 2024 0.46
Dec 31, 2023 0.44
Sep 30, 2023 0.44
Jun 30, 2023 0.44
Mar 31, 2023 0.43
Dec 31, 2022 0.43
Sep 30, 2022 0.43
Jun 30, 2022 0.44
Mar 31, 2022 0.42
Dec 31, 2021 0.40
Sep 30, 2021 0.41